[Journal of Nanobiotechnology] Investigators provided a basis for further development of combination immunotherapy strategies for poorly immunogenic breast cancer, including strategies to improve responses to checkpoint blockade.

[Molecular Therapy] With the goal of enhancing oncolytic virotherapy independently of E2, scientists designed a treatment strategy that combines oncolytic Vesicular stomatitis virus with the NF-κB inhibitors IKK16 and Sulfasalazine and found that both drugs improved virus replication in TNBC cell lines and patient samples.

[Proceedings of the National Academy of Sciences of the United States of America] Researchers showed that BRCA1P1 expression varies across multiple cancer cell types, with no significant association with BRCA1 or BRCA2 somatic mutations in breast and ovarian tumors.

[Sapu Nano (Globe Newswire)] First-in-human study evaluates weekly IV Sapu003 in advanced mTOR-sensitive solid tumors, including HR+/HER2- breast cancer, RCC, NETs, TSC-associated tumors, and HCC.

[NPCF (PR Newswire)] The National Pediatric Cancer Foundation (NPCF) has awarded a $1 million research grant to Dr. JinSeok Park to support mechanistic and translational research targeting metastatic fusion‑positive rhabdomyosarcoma, a rare, clinically aggressive pediatric sarcoma characterized by the PAX3‑FOXO1 fusion oncoprotein.

[FUJIFILM Biosciences] FUJIFILM Biosciences and NextCell Pharma AB announced a global launch resulting from their collaboration. The offering consists of FUJIFILM Biosciences' PRIME-XV MSC Expansion XSFM medium and NextCell-Cord RUO, a research-use-only (RUO) MSC product derived from umbilical cord tissue.

[Blood] Scientists identified a subset of Procr+ endothelial cells (ECs) with progenitor-like properties in bone marrow. Procr binds HSPA8 to promote Foxc2 nuclear translocation, upregulating Dll4 transcription to sustain Dll4/Notch3 activation in MSCs, revealing a Procr/HSPA8/Foxc2/Dll4 axis essential for EC and MSC crosstalk.

[Cell Death & Disease] The authors summarize the latest evidence regarding the temporal therapeutic role of MSCs via the “immune-mitochondrial” axis at different stages of cerebral ischemia-reperfusion injury. They elucidate the role of mitochondria as a central hub connecting metabolic crisis and immune storm.

[Stem Cells] Scientists highlight the diverse therapeutic roles of MSCs and their derivatives, such as exosomes and engineered vectors, in brain tumor management.

[Stem Cell Reviews and Reports] Investigators synthesize emerging evidence on MSC priming for tendon regeneration, assess its histological and biomechanical foundations, and elucidate its translational potential for achieving biologically integrated and clinically durable rotator cuff repair.

[Stem Cell Research & Therapy] The authors evaluate the therapeutic efficacy and potential mechanisms of bone marrow-derived MSCs, adipose-derived stromal cells, umbilical cord-derived MSCs, synovium-derived MSCs, ESC-derived MSCs and iPSC-derived MSCs in modulating the joint microenvironment.

[Brain] This Phase I/IIa study analyzed safety and treatment effect of three intravenous infusions of autologous adipose-derived MSCs in 24 chronic traumatic brain injury patients.